Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 251

The DOI matches its Crossref record.

A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer.

Jain, K K, Casper, E S, Geller, N L, Hakes, T B, Kaufman, R J, Currie, V, Schwartz, W, Cassidy, C, Petroni, G R, Young, C W · 1985 · Journal of Clinical Oncology

Abstract

Fifty-four patients with advanced breast cancer who had failed prior non-anthracycline combination chemotherapy were randomized to treatment with either epirubicin 85 mg/m2 or doxorubicin 60 mg/m2 intravenously every three weeks. Of 52 evaluable patients, 25% (six of 24) treated with epirubicin, and 25% (seven of 28) treated with doxorubicin experienced major therapeutic responses. The median duration of response to epirubicin was 11.9 months compared to 7.1 months with doxorubicin. Cardiotoxicity was monitored by serial multigated radionuclide cineangiocardiography performed at rest and after exercise. Laboratory evidence of cardiotoxicity was defined as a decrease in resting left ventricular ejection fraction of greater than 10% from the baseline value, or a decrease of 5% or greater with exercise compared with the resting study performed on the same day. Fifteen patients treated with epirubicin and 18 patients treated with doxorubicin had at least two determinations of left ventricular ejection fraction and were evaluable for laboratory cardiotoxicity. Using methods of survival analysis, the median doses to the development of laboratory cardiotoxicity were estimated to be 935 mg/m2 of epirubicin and 468 mg/m2 of doxorubicin. Four patients treated with epirubicin and five treated with doxorubicin developed symptomatic congestive heart failure. The median cumulative dose at which congestive heart failure occurred was 1,134 mg/m2 of epirubicin compared with 492 mg/m2 of doxorubicin. Fewer episodes of nausea and vomiting were observed in patients receiving epirubicin. Epirubicin is a new anthracycline with reduced cardiac toxicity, but preserved efficacy in the treatment of patients with advanced breast cancer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.1985.3.6.818

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 251

Metadata

Authors
Jain, K. K., Casper, E. S., Geller, N. L., Hakes, T. B., Kaufman, R. J., Currie, V, Schwartz, W., Cassidy, C., Petroni, G. R., & Young, C. W.
Venue
Journal of Clinical Oncology
Published
1985-06
Volume
3
Issue
6
Pages
818-826
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W1888375872
Cited by
251
References
0
FWCI
4.33
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. https://app.cochat.ai/papers/10.1200/jco.1985.3.6.818
The paper
Jain, K. K., Casper, E. S., Geller, N. L., Hakes, T. B., Kaufman, R. J., Currie, V, Schwartz, W., Cassidy, C., Petroni, G. R., & Young, C. W. (1985). A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1985.3.6.818

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.